Praxis Program Nets $1.8M Savings
Praxis, the Brentwood, TN-based centralized patient recruitment and retention company, announced the status of a current recruitment and retention program for a top pharmaceutical company currently studying a mental health issue in Phase III.
Praxis is providing services for two studies in Phase III, for which it had successfully completed a prior Phase III recruitment initiative. While the trials seek different patient populations, they are complimentary. Because of this, Praxis was able to develop an umbrella program for the sponsor under which both protocols can be effectively and simulatneously recruited. Based on the umbrella program, the sponsor was able to save $1.8 million in clinical program costs.
Praxis used both past experience in mental health studies, with the predictive modleing of its PraxisDirect 2.0 software to design the program to meet enrollment goals. Nearly 2,000 patients will be randomized across 75 sites within a nine-month period. Praxis has experience with mental health areas including bipolar depression, major depressive disorder (MDD), and bipolar mania.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
